
|Articles|April 27, 2004
VIM Trial results favor PDT for small, subfoveal minimally classic,AMD-related CNV
Verteporfin (Visudyne) photodynamic therapy (PDT) using either a reducedor standard light fluence rate appears to be beneficial for patients withrelatively small, subfoveal minimally classic CNV associated with age-relatedmacular degeneration (AMD), said Philip J. Rosenfeld, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: What’s in the glaucoma treatment pipeline?
2
FDA grants single-patient expanded access for urcosimod in neuropathic corneal pain
3
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
4
2026 from an OD's perspective: What is on the horizon
5



























